Suggested remit -To appraise the clinical and cost effectiveness of ivosidenib within its marketing authorisation for treating adults with relapsed or refractory acute myeloid leukaemia which is isocitrate dehydrogenase-1 R132 mutation-positive who are not eligible for intensive treatment including HSCT.
Following on from information provided to NICE by the company in December 2020 the appraisal of Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1548
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 December 2022 | Discontinued. Following on from information provided to NICE by the company in December 2020 the appraisal of Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 10 December 2020 | Note added to the project documents |
| 10 December 2020 | Suspended. Topic is suspended |
| 19 May 2020 | Note added to the project documents |
| 21 November 2019 | Note added to the project documents |
| 29 March 2019 | Note added to the project documents |
| 22 March 2019 | Awaiting development. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late January 2020 when we will write to you about how you can get involved. |
| 22 March 2019 | In progress. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late January 2020 when we will write to you about how you can get involved. |
| 17 October 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual